You are viewing the site in preview mode
Skip to main content
|
N (%), unless indicated
|
Overall
|
JIAa alone (n = 22)
|
JIA-Ub (n = 22)
|
Other Uc (n = 18)
|
|---|
|
Characteristics
| | | | |
|
Demographics
| | | | |
|
Age, Mean (SD)d
|
13.0 (3.3)
|
12.9 (2.8)
|
12.6 (3.4)
|
13.5 (3.9)
|
|
Gender, Male
|
14 (22.6)
|
2 (9.1)
|
4 (18.2)
|
8 (44.4)
|
|
Race
|
|
White
|
53 (85.5)
|
21 (95.5)
|
20 (90.9)
|
12 (66.7)
|
|
African American
|
5 (8.1)
|
1 (4.5)
|
1 (4.5)
|
3 (16.7)
|
|
American Indian/Alaskan Native
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
|
Asian
|
1 (1.6)
|
0 (0.0)
|
1 (4.5)
|
0 (0.0)
|
|
Multi-racial
|
1 (1.6)
|
0 (0.0)
|
0 (0.0)
|
1 (5.6)
|
|
Unknown/Declined
|
2 (3.2)
|
0 (0.0)
|
0 (0.0)
|
2 (11.1)
|
|
Ethnicity, Hispanic
|
1 (1.6)
|
0 (0.0)
|
1 (4.7)
|
0 (0.0)
|
|
JIA Characteristics
|
|
Age at Diagnosis, Mean (SD)
|
6.3 (4.6)
|
7.7 (4.3)
|
4.9 (4.2)
| |
|
Duration of Disease, years, Mean (SD)
|
6.5 (4.3)
|
5.2 (3.7)
|
7.7 (4.7)
| |
|
JIA Subtype
|
|
Oligoarticular Persistent
|
14 (31.8)
|
10 (45.5)
|
4 (18.2)
| |
|
Oligoarticular Extended
|
9 (20.5)
|
3 (13.6)
|
6 (27.3)
| |
|
Polyarticular RF(-)
|
17 (38.6)
|
9 (40.9)
|
8 (36.4)
| |
|
Uveitis Characteristics
|
|
Age at Diagnosis, Mean (SD)
|
8.4 (4.5)
| |
6.1 (4.0)
|
11.4 (3.0)
|
|
Duration of Disease, years, Mean (SD)
|
4.8 (4.3)
| |
6.4 (4.7)
|
2.8 (2.8)
|
|
Bilateral Disease
| | |
17 (77.2)
|
12 (66.7)
|
|
Anterior Chamber Cells >0.5+
| | |
1 (4.6)
|
2 (11.1)
|
|
Visual Acuity 20/50 or worse
| | |
0 (0.0)
|
0 (0.0)
|
|
Location
| | | | |
|
Anterior
| | |
22 (100.0)
|
13 (72.2)
|
|
Intermediate
| | |
1 (4.5)
|
3 (1.7)
|
|
Posterior
| | |
0 (0.0)
|
1 (5.5)
|
|
Panuveitis
| | |
0 (0.0)
|
2 (11.1)
|
|
Ocular Complications, ever
|
|
Glaucoma or Glaucoma Suspect
|
21 (33.9)
| |
11 (50.0)
|
10 (55.6)
|
|
Cataracts
|
16 (25.8)
| |
10 (45.5)
|
6 (33.3)
|
|
Synechiae
|
11 (17.7)
| |
8 (36.4)
|
3 (16.7)
|
|
Band Keratopathy
|
4 (6.5)
| |
1 (4.5)
|
3 (16.7)
|
|
Amblyopia
|
3 (4.8)
| |
2 (9.1)
|
1 (5.6)
|
|
Cystoid Macular Edema
|
1 (1.6)
| |
1 (4.5)
|
0 (0.0)
|
|
Othere
|
1 (1.6)
| |
0 (0.0)
|
1 (5.6)
|
|
Treatment, at time of visit
|
|
Steroid drops
|
24 (38.7)
| |
11 (50.0)
|
13 (72.2)
|
|
Dilating drops
|
2 (3.2)
| |
2 (9.1)
|
0 (0.0)
|
|
IOP-lowering dropsf
|
5 (8.1)
| |
1 (4.5)
|
4 (22.2)
|
|
Methotrexate oral
|
12 (19.4)
|
5 (22.7)
|
5 (22.7)
|
2 (11.1)
|
|
Methotrexate SQ
|
10 (16.1)
|
3 (13.6)
|
4 (18.2)
|
3 (16.7)
|
|
Mycophenolate
|
2 (3.2)
|
0 (0.0)
|
1 (4.5)
|
1 (5.6)
|
|
Etanercept
|
4 (6.5)
|
4 (18.2)
|
0 (0.0)
|
0 (0.0)
|
|
Infliximab
|
12 (19.4)
|
1 (4.5)
|
6 (27.3)
|
5 (27.8)
|
|
Adalimumab
|
9 (14.5)
|
2 (9.1)
|
6 (27.3)
|
1 (5.6)
|
|
Abatacept
|
1 (1.6)
|
0 (0.0)
|
1 (4.5)
|
0 (0.0)
|
|
Tocilizumab
|
7 (11.3)
|
3 (13.6)
|
4 (18.2)
|
0 (0.0)
|
- aJIA: juvenile idiopathic arthritis; bJIA-U: JIA-associated uveitis; cOther U: all other uveitis not associated with JIA; d SD: standard deviation; eOther complications include: vitreous hemorrhage, optic disc edema, aphakia, choroidal neovascular membranes, choriorential scare, retinal neovascularization, retinal detachment, keratic precipitates, peri retinal fibrosis, floaters, blindness, ocular hypertension; fIOP: Intraocular pressure
